Are ezetimibe and Vascepa contraindicated together in liver disease?
No, ezetimibe (Zetia) and icosapent ethyl (Vascepa) are not contraindicated when used together in patients with liver disease. Their prescribing information does not list a specific contraindication for this combination in hepatic impairment. Ezetimibe is contraindicated only in active liver disease with unexplained persistent elevations in hepatic transaminases or hypersensitivity, while Vascepa carries no hepatic contraindications but requires monitoring in moderate-to-severe liver disease.[1][2]
What do the labels say about each drug in liver disease?
Ezetimibe's label contraindicates it in active liver dysfunction with persistent transaminase elevations (>3x ULN), based on rare post-marketing reports of hepatitis and rare cases of fatal liver failure. It is not recommended during co-administration with statins in advanced liver disease but has no such restriction with Vascepa. Vascepa's label notes no dosage adjustment for mild-to-moderate hepatic impairment (Child-Pugh A/B), but data are limited in severe impairment (Child-Pugh C); elevated ALT/AST occurred in 3% of patients, mostly mild.[1][2]
Any known interactions between ezetimibe and Vascepa?
No clinically significant pharmacokinetic or pharmacodynamic interactions are documented between ezetimibe and Vascepa. Ezetimibe inhibits intestinal cholesterol absorption without CYP450 effects, while Vascepa, a purified EPA ethyl ester, undergoes beta-oxidation with minimal CYP involvement. Drug interaction checkers like Lexicomp and Drugs.com report no interactions.[3]
How should liver disease patients be monitored on this combo?
Monitor liver enzymes (ALT/AST) before starting and periodically, especially if baseline abnormalities exist. Discontinue ezetimibe if transaminases exceed 3x ULN persistently. For Vascepa, watch for bleeding risk or myopathy in severe liver disease, though these are not amplified by ezetimibe. Clinical trials like REDUCE-IT (Vascepa) excluded severe liver disease but included patients on statins, some with ezetimibe.[1][2][4]
What alternatives exist for lipid management in liver disease?
In mild liver impairment, fibrates like fenofibrate may be used cautiously instead of Vascepa, but they risk worsening transaminitis. Bempedoic acid avoids statin-related liver issues and pairs well with ezetimibe. For triglycerides, omega-3 formulations like Lovaza have similar hepatic cautions to Vascepa.[1][5]
[1]: Ezetimibe Prescribing Information (Merck)
[2]: Vascepa Prescribing Information (Amarin)
[3]: Drugs.com Interaction Checker
[4]: REDUCE-IT Trial (NEJM)
[5]: Bempedoic Acid Label (Nexletol)